THC + CBD oromucosal spray
Cannabis extract
Brand names: Sativex (nabiximols)
Adult dose
Dose: Titrate from 1 spray daily, increase by 1 spray/day to max 12 sprays/day
Route: Oromucosal
Frequency: Up to QDS
Clinical pearls
- NICE NG144 cannabis-based medicinal products: severe MS spasticity unresponsive to other antispasmodics
- ABN MS spasticity / NICE TA review
- Specialist neurology; trial-of-treatment with documented benefit at 4 weeks
Contraindications
- Personal/family history of psychosis
- Severe cardiovascular disease
- Pregnancy/breastfeeding
- Children
- Hypersensitivity
Side effects
- Dizziness
- Fatigue
- Mood change
- Hallucinations
- Tachycardia
- Falls
- Dependence (theoretical)
Interactions
- CNS depressants
- Strong CYP3A4 inhibitors/inducers
Monitoring
- Spasticity score
- Mental state
- Cardiovascular tolerance
- Driving (DVLA)
Reference: BNF; NICE NG144; ABN MS spasticity; SmPC; https://bnf.nice.org.uk/drugs/cannabis-extract/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Pathways
- Acute Stroke / TIA Assessment · NICE NG128; RCP Stroke Guidelines 2023
- Status Epilepticus (Adults) · NICE CG137; ESEM guidelines; RCP Neurology Guidelines
- Suspected Subarachnoid Haemorrhage · NICE NG228; RCEM 2023; AHA/ASA 2023
- Adult Head Injury · NICE NG232 (2023)
- Bell's Palsy / Facial Nerve Palsy · ENT UK 2017; AAN
- Vertigo Workup · ENT UK; NICE CKS